Data Mining for Drug Repurposing and New Targets Identification for Radioprotection

  • Yogesh Kumar Verma Division of Stem Cell and Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences, Delhi
  • Gurudutta Gangenahalli Division of Stem Cell and Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences, Delhi
Keywords: Radioprotective agents, Network based drug discovery, Gene-drug mapping, Radiation induced genes, Amifostine, Microarray

Abstract

Ionising radiation (IR) is responsible for various types of tissue injury leading to morbidity at low doses and mortality at high radiation exposure. Although many radioprotective and pharmacological agents are being tested for decreasing radiation injury, however, the availability of Amifostine as the only clinically used radioprotector with limited indication has prompted us to find out new potential molecules through drugs repurposing for protecting or decreasing radiation damage by data mining. In this work we have used text-mining based network generation approach to find out the gene targets of radioprotectors under evaluation by Agilent Literature Search app in Cytoscape. Extracted genes were evaluated for their association with radiation in Radiation Genes database. These genes were searched against therapeutic drugs and molecules under clinical trial in the Drug Gene Interaction database. We found that most of the radiation target genes were involved in cell death, proliferation, homeostasis, cell cycle and cancer pathways. Many of these genes were druggable and could be targeted by the drugs under clinical research, whereas there were few genes (new targets), which were never considered for radioprotective drug development. This study would likely help in repurposing of identified drugs for use in the event of radiation fallout, keeping in mind that no radiation medical countermeasure for acute radiation syndrome has been approved by the US FDA for use in humans. Results also revealed new target genes for drug targeting and indicates use of similar pipeline in other pathologies for drug repurposing and development.

Author Biographies

Yogesh Kumar Verma, Division of Stem Cell and Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences, Delhi

Dr Yogesh Kumar Verma, completed his MSc and PhD in Biomedical Science from Delhi University. Presently working as Scientist ‘D’ in Institute of Nuclear Medicine and Allied Sciences, Delhi. He has 21 publications and 03 patents (filed) to his credit. He is presently working in the area of stem cell research, microencapsulation, tissue engineering and omics data mining and analysis for decreasing various types of injuries.

Gurudutta Gangenahalli, Division of Stem Cell and Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences, Delhi

Dr Gurudutta Gangenahalli, presently an Additional Director and Head of the Division of Stem Cell Research at Institute of Nuclear Medicine and Allied Sciences, Delhi. He worked in the area of therapeutic potential human stem cell fate response signaling, such as apoptosis, adherence, osteogenesis, differentiation, homing, by using genetic-engineering of human stem cell genes (of CD34, BCL-2, CXCR4, PU.1, SCFr/c-Kit, APC, OSx, Wnt etc) and by High-throughput gene-expression analysis. He is also working on developing the human stem cell shielding formulations and NMR stem cell tracking methods.

Published
2017-08-03
How to Cite
Verma, Y., & Gangenahalli, G. (2017). Data Mining for Drug Repurposing and New Targets Identification for Radioprotection. Defence Life Science Journal, 2(3), 343-353. https://doi.org/10.14429/dlsj.2.11671